August 12th 2020
Nina Shah, MD, discusses the updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.
Thomas G. Martin, MD, discusses the safety profile of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.
August 11th 2020
Betsy O'Donnell, MD, discusses ongoing research efforts in multiple myeloma.
A new subcutaneous formulation, daratumumab and hyaluronidase-fihj, provides similar efficacy in a more convenient and efficient regimen that is likely to change practice.
August 6th 2020
Noopur S. Raje, MD, discusses recent findings with melflufen in relapsed/refractory multiple myeloma.
Luciano J. Costa, MD, PhD, discusses unmet needs in relapsed/refractory multiple myeloma.
Sagar Lonial, MD, FACP, discusses the FDA approval of belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
The FDA has approved belantamab mafodotin-blmf (Blenrep) as a treatment for patients with relapsed/refractory multiple myeloma who have received 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.
August 5th 2020
Noopur S. Raje, MD, discusses remaining questions in multiple myeloma.
August 4th 2020
Shaji K. Kumar, MD, discusses treatment discontinuation in the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.
